Skip to main content

Table 2 Quality assessment of included studies

From: Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis

Study

Random sequence generation

Allocation concealment

Blinding of participants and personnel

Blinding of outcome assessment

Incomplete outcome data

Selective reporting

Bias from other resources

Shruti R. Tiwari 2016 [25]

Low risk

Unclear

Unclear

Low risk

Low risk

Low risk

Low risk

Sandra M.Swain 2015 [19]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Sabino De Placido 2018 [33]

Low risk

High risk

Unclear

Low risk

Low risk

Low risk

Low risk

Rashmi K. Murthy 2018 [17]

Low risk

Unclear

Low risk

Low risk

High risk

Low risk

Low risk

Peter Beitsch 2017 [10]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Nicholas J. Robert 2017 [32]

Low risk

Unclear

Unclear

Low risk

Low risk

Low risk

Unclear

Nadia Hussain 2018 [35]

Unclear

Unclear

Unclear

Low risk

Low risk

Low risk

Low risk

Mothaffar Rimawi 2017 [18]

Low risk

Unclear

Low risk

Low risk

Low risk

Low risk

Low risk

Andersson M 2017 [26]

Low risk

Unclear

Low risk

Low risk

Low risk

Low risk

Low risk

Manish Gupta 2013 [11]

High risk

Low risk

Low risk

Low risk

High risk

High risk

Unclear

M. Martin 2016 [13]

High risk

Unclear

Low risk

Low risk

Low risk

Low risk

Low risk

Luca Gianni 2018 [22]

Low risk

Unclear

Low risk

Low risk

Low risk

Low risk

High risk

Luca Gianni 2012 [15]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Kazuhiro Araki 2017 [14]

Low risk

Low risk

Unclear

Unclear

Low risk

Low risk

High risk

Kathy D. Miller 2014 [34]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Julia Foldi 2017 [23]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

José Baselga 2010 [30]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

JASMEET C. SINGH 2017 [24]

Unclear

Unclear

Low risk

Low risk

Low risk

Low risk

Unclear

Ian E.Krop 2016 [20]

Low risk

Unclear

Low risk

Low risk

Low risk

High risk

Low risk

Gunter von Minckwitz 2017 [16]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Edith A. Perez 2017 [21]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Edith A. Perez 2016 [27]

Low risk

Unclear

Low risk

Low risk

Low risk

Low risk

Low risk

Chia C. Portera 2008 [31]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Chau Dang 2015 [28]

Low risk

Unclear

Low risk

Low risk

Low risk

Low risk

Low risk

Bao D Dao 2015 [29]

Unclear

Unclear

Low risk

Low risk

Low risk

Low risk

Unclear

Ander Urruticoechea 2017 [9]

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk